Tumor necrosis factor (TNF-alpha) (TNF-alpha)

Tumor necrosis factor (TNF), specifically the soluble form (sTNF-α), is a potent pro-inflammatory cytokine that plays a central role in the regulation of immune cells and systemic inflammation (UniProt, 2024). It is initially produced as a 26 kDa transmembrane protein (tmTNF) by activated macrophages, monocytes, and T-cells, which is then proteolytically cleaved by the TNF-alpha converting enzyme (TACE/ADAM17) to release the 17 kDa soluble homotrimer (NCBI, 2024). Soluble TNF-α primarily exerts its biological effects by binding to the TNF receptor 1 (TNFR1), triggering intracellular signaling pathways such as NF-κB and MAP kinase that promote inflammation, cell survival, or apoptosis (StatPearls, 2023). Pathologically high levels of sTNF-α are associated with the development and progression of various autoimmune and inflammatory conditions, including rheumatoid arthritis, psoriasis, and inflammatory bowel disease (PubMed, 2023). Therapeutic intervention typically involves the use of monoclonal antibodies or decoy receptors that bind and neutralize sTNF-α, thereby preventing its interaction with cell-surface receptors and dampening the inflammatory response (NIH, 2024). While most current biologics neutralize both soluble and transmembrane forms, newer investigational agents aim to selectively target sTNF-α to preserve the beneficial immune functions of tmTNF (Nature, 2021). These therapies are highly effective but carry risks such as increased susceptibility to serious infections and the potential reactivation of latent tuberculosis (FDA, 2023).

Other names

TNF-αCachectinTumor necrosis factor ligand superfamily member 2TNFSF2Soluble TNF-alpha

Neutralization of soluble and/or transmembrane TNF-alpha to prevent binding to TNF receptors (TNFR1 and TNFR2), thereby inhibiting pro-inflammatory signaling cascades (StatPearls, 2023).